Cell Therapy News

Researchers studied the potential of AAV9.hCLN2 #GeneTherapy for neuronal ceroid lipofuscinosis type 2 (CLN2) disease using innovative human-relevant microphysiological retinal disease models. 📖 More in @CellRepMed: bit.ly/3IGR7KH

Researchers led by Dr. @sahakris evaluate a novel molecular glue degradation system, called Cas9-degron, designed to degrade Cas9 in the presence of the FDA-approved drug pomalidomide. 👉 bit.ly/3GXeDme

This @CellRepMed review addresses the integration of CAR-T cell therapy with reconstructive oncologic surgery in treating peripheral solid tumors, including melanoma, sarcomas, breast cancer, and head and neck cancers. ✅ Check it out! bit.ly/4lUESZe

In this recent @CellRepMed article, Dr. Kauke-Navarro and team highlight CAR-T cell therapy as a potential adjunctive treatment in oncologic surgery. 💡Learn more: bit.ly/4lUESZe

Collaborators, including @KRejeski & @JoshuaHillMD, discuss noncanonical and mortality-defining toxicities of CAR T cell therapy. ✅ Check out their review in @NatureMedicine! go.nature.com/4ltZUy8

A research team from Zhejiang University show that bispecific killer cell engager-secreting CAR-T cells redirect natural killer specificity to enhance antitumor responses. @natBME | go.nature.com/44T0nmE

A Soochow University research team engineered dynamically covalent lipid nanoparticles to mediate VEGFA gene editing and choroidal neovascularization treatment by codelivering Cas9 mRNA and single guide RNA targeting VEGFA. 🧫🛠️ bit.ly/3THnkEc

⏱️ Final week to enter! Subscribe to one of our 20 immunology or cell biology newsletters before July 18 for a chance to win a personalized lab coat. bit.ly/3YYyzuM

Check out this new #review from the @Menendez_Lab at @CarrerasIJC! 👇 It discusses the current challenges and future directions of #CARTCell therapy for cancer. 📑 Read it in @sigtrans_sttt: go.nature.com/46ByiT2

Scientists have developed an #OssificationCenter-like #organoid that consist of an inner-core bone morphogenetic and neurotrophic spheroid, alongside the interstitially distributed outer-shell proangiogenic neurotrophic phase. 🦴 Read the @NatureComms study:…

Researchers from Zhengzhou University have characterized the immune microenvironment of a secondary chronic myelomonocytic leukemia post-#CARTCell therapy. 🔬 Read the @ChinMedJ study: bit.ly/4lL7Cnp

Researchers have conducted a single-arm trial of an AAV-OTOF #GeneTherapy using the Anc80L65 capsid in ten participants with autosomal recessive #deafness 9. 📓 Read the results in @NatureMedicine: go.nature.com/44QpeZc

A retrospective study led by Dr. Zainab Shahid (@ZainabShd) at @MSKCancerCenter has analyzed #vaccine responses in patients who received post-#CARTCell therapy vaccination between 2018 and 2024. 💉 Read the @BloodCancerJnl study: go.nature.com/44LBNFf

Researchers led by Dr. Nadia Coltella & Luigi Naldini show that cross-talk established by tumor-targeted cytokines rescues CAR T cell activity and engages host T cells against #glioblastoma in mice. 🐭 @ScienceTM | bit.ly/3G6XaHO

Novel pre-clinical trial platform recreates human #BoneMarrow and immune system to predict cancer #immunotherapy success in patients. Congratulations to Dr. Weiqiang Chen and team on this study! 👏 🧪 go.nature.com/401LmgJ 🗞️ bit.ly/4lfcSjj

Fresh off the press! ♨️ Scientists, including @_amandachen & @paulbeavis4, developed a #CRISPR knock-in strategy that leverages the regulatory mechanisms of endogenous genes to drive transgene expression in a tumor-localized manner. @nature | go.nature.com/3I8Nk8S

Do you think AAV mediated #GeneTherapy can achieve durable and functional expression of human FVII in vivo? 🤔 📖 Read this study by Dr. @VoorbergJ and team where they explored just that. bit.ly/3TiRzkt

This @ScienceAdvances study shows a highly conserved NY-ESO-1 TCRαβ variable chain usage that confers potent antigen-specific effector functions against various tumor types. 💡 Learn more from Dr. Camilla Jandus and team! bit.ly/449dAsd

Join the 4th Process Development for Cell Therapies Summit to gain insights into how to develop consistent, scalable, and cost-effective solutions for both autologous and allogeneic cell therapies. Avail 10% off registration: MPDISCPDCT10 ter.li/1rucpq

New in @NatureMedicine! Dr. Perry Shieh 's team shares results from a Phase Ib trial of AAV mini-dystrophin #GeneTherapy for Duchenne muscular dystrophy. 🧬 Check it out! go.nature.com/3TbezC1